Presentation on theme: "Colorectal Cancer Center Jena 18.05.2011 Introduction In Germany, there are currently approximately 70 000 newly diagnosed patients with colorectal carcinoma."— Presentation transcript:
Colorectal Cancer Center Jena 18.05.2011 Introduction In Germany, there are currently approximately 70 000 newly diagnosed patients with colorectal carcinoma each year, 60% of these have distant metastases at the time of diagnosis. The University Colorectal Cancer Center Jena will be certified in May 24th 2011 by the German Cancer Society (Deutsche Krebsgesellschaft). In 2010, 104 patients with newly diagnosed colorectal carcinoma have been treated at the University Colorectal Cancer Center Jena. It is the aim of the University Colorectal Cancer Center Jena to offer affected patients a multi-modal treatment concept with the best possible options for cure by multidisciplinary cooperation. TRIAL NAMETRIAL DESIGN PETACC 6Preoperative radio-chemotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine for locally advanced rectal carcinoma PANTERPerioperative chemotherapy for resectable colorectal liver metastases with FOLFOX plus possibly cetuximab vs. adjuvant chemotherapy with FOLFOX plus possibly cetuximab ML 22011Capecitabine plus bevacizumab vs. capecitabine plus irinotecan plus bevacizumab as first-line- treatment for metastasizing (non-resectable) colorectal carcinoma FIRE 3Randomized phase II trial on the efficacy of FOLFIRI in combination with cetuximab vs. bevacizumab as first-line-treatment for metastasizing colorectal carcinoma Cooperating partners and multidisciplinary cooperation Specific competence and expertise Current clinical trials Contact point for patients with colorectal carcinoma is the daily surgical out-patient clinic and the specialized colorectal consultation once a week on Friday. Possibility to have a second opinion through the University Tumor Center (UTC) out-patient clinic is given. After first contact, patients will be included in special clinical pathways und discussed at a tumor board convening once per week (Monday) with all cooperating and at the University Hospital Jena available clinical specialties participating, and a treatment concept according to guidelines will be developed. Cooperation with the UTC occurs especially in documentation for tumorboard preparation. Data evaluation will be done by the Clinical Cancer Registry. Main cooperating partners: -Department of General, Visceral and Vascular Surgery -Department of Internal Medicine II – Subsection hematology, oncology -Department of Radiation Therapy and Radio-oncology -Institute for Pathology -Department of Internal Medicine II – Subsection gastroenterology, hepatology, infectious diseases -Institute for Diagnostic and Interventional Radiology Other cooperating partners: -Institute for Psychosocial Medicine and Psychotherapy (psycho-oncological patient care) -Clinic for Pain and Palliative Care -Clinic for Human Genetics (Center for Out-patient Care of the University Hospital Jena) -Deutsche ILCO e.V. (patient´s advocacy group) The University Colorectal Cancer Center Jena offers patients with colorectal carcinoma state-of-the-art treatment options: - Laparoscopic resections of colon and rectum carcinomas at early tumor stages - Liver resections for metastatic disease (anatomical as well as extended and atypical) - Sequential treatment for bilateral liver metastases (e.g. portal vein embolization, open or percutaneous radio frequency ablation) Conclusion The following clinical trials are currently underway at the University Colorectal Cancer Center Jena, recruiting patients with colorectal carcinoma: Colorectal carcinoma is the second-most frequent tumor disease (after bronchial and breast cancer,respectively) in Germany and the numbers are increasing. An improvement of long-term and recurrence-free survival can only be achieved by further multidisciplinary cooperation of all clinical specialties involved, by the establishment of multi-modal treatment concepts and by advances in research. The development of special organ centers within the framework of UTC is the best way to reach this goal by standardizing pathways and treatment.